%0 Journal Article
%A Hennrich, Ute
%A Eder, Matthias
%T [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer.
%J Pharmaceuticals
%V 15
%N 10
%@ 1424-8247
%C Basel
%I MDPI
%M DKFZ-2022-02558
%P 1292
%D 2022
%Z #EA:W630#
%X In March 2022, [177Lu]Lu-PSMA-617 (PluvictoTM) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such as inhibition of the androgen receptor pathway and taxane-based chemotherapy). [177Lu]Lu-PSMA-617, which combines a PSMA-specific peptidomimetic with a therapeutical radionuclide, is used in a radioligand therapy that selectively delivers ionizing radiation to tumor cells, causing their death, while sparing the surrounding healthy tissue. In numerous clinical trials, the efficacy of [177Lu]Lu-PSMA-617 was demonstrated.
%K PSMA (Other)
%K PluvictoTM (Other)
%K [177Lu]Lu-PSMA-617 (Other)
%K prostate cancer (Other)
%K radioligand therapy (RLT) (Other)
%K theranostics (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36297404
%R 10.3390/ph15101292
%U https://inrepo02.dkfz.de/record/182301